Viridian Therapeutics, Inc. - Common Stock — Quarterly Balance Sheet (NASDAQ:VRDN) | MetaTrader

Open full chart

News

VRDN Stock Rises 6.3% in a Week: Here's What You Need to Know

Viridian Therapeutics, Inc. (VRDN) Discusses FDA Approval and Launch Plans for Lumvoa as a New Therapy for Thyroid Eye Disease - Slideshow (NASDAQ:VRDN) 2026-07-01

Viridian Therapeutics, Inc. (VRDN) Discusses FDA Approval and Launch Plans for Lumvoa as a New Therapy for Thyroid Eye Disease Transcript

Viridian Secures First FDA Approval, Sets Up Challenge To Amgen's Tepezza For Thyroid Eye Disease - Virid

Nasdaq futures lead Wall St higher as Middle East tensions ease

Viridian Therapeutics (VRDN): Two-Step TED Franchise With More Leverage Than Market Likes

Viridian Therapeutics, Inc. (VRDN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Viridian Therapeutics, Inc. (VRDN) Discusses Positive Top Line Results From REVEAL-2 Phase III Trial in Chronic Thyroid Eye Disease - Slideshow (NASDAQ:VRDN) 2026-05-09

Viridian Therapeutics, Inc. (VRDN) Discusses Positive Top Line Results From REVEAL-2 Phase III Trial in Chronic Thyroid Eye Disease Transcript

Can This Small Rival Take On Amgen's Eye Disease Blockbuster?

Viridian Therapeutics: Why Elegrobart Phase 3 Results Fail To Challenge Amgen (NASDAQ:VRDN)

Amgen Unveils Upbeat Results For Tepezza After Rival Eye Disease Drug Disappoints